Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Inflammatory Biomarker Reduction With Fostemsavir Over 96 Weeks in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 in the BRIGHTE Study.
Journal: Open forum infectious diseases
Published: April 30, 2024
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.
Journal: Frontiers in immunology
Published: March 01, 2024
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.
Journal: Infectious diseases and therapy
Published: July 02, 2023
Model-Based Dose Selection of Fostemsavir for Pediatric Populations With Multidrug-Resistant HIV-1 and Relative Bioavailability Assessment in Healthy Adults.
Journal: Clinical pharmacology in drug development
Published: January 27, 2023
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
Journal: Antimicrobial agents and chemotherapy
Published: May 03, 2022
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Journal: The lancet. HIV
Published: April 30, 2020
Steroid-exacerbated HIV-associated cutaneous Kaposi's sarcoma immune reconstitution inflammatory syndrome: 'Where a good intention turns bad'.
Journal: International journal of STD & AIDS
Published: November 18, 2015
Fatal multiple deer tick-borne infections in an elderly patient with advanced liver disease.
Journal: BMJ case reports
Published: March 04, 2015
Deep sequencing of HIV: clinical and research applications.
Journal: Annual review of genomics and human genetics
Published: May 14, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026